Evidence map›Paper›PMID 39757611›Full record

ArticleInfectious disorders drug targets2025

Exploring the Potential Use of

Pugazhenthan Thangaraju, Thiyagarajan Saraswathy, Hemasri Velmurugan, Sajitha Venkatesan, Sree Sudha Ty, Pankaj Maheshwari, Ray Radha Sargunam, Alagesan Srinivasan, Eswaran Thangaraju, Tamilselvan Thangaraju

Abstract read
PubMed Publisher
In one paragraph

Article in Infectious disorders drug targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Pugazhenthan ThangarajuDepartment of Pharmacology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India.ORCID 0000-0002-4090-2004
Thiyagarajan SaraswathyDepartment of Pharmaceutical Chemistry, College of Pharmacy, Madras Medical College, Chennai, India.
Hemasri VelmuruganDepartment of Pharmacology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India.ORCID 0000-0002-1388-957X
Sajitha VenkatesanDepartment of Microbiology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India.
Sree Sudha TyDepartment of Pharmacology, All India Institute of Medical Sciences, Deoghar, Jharkhand, India.
Pankaj MaheshwariSenior Divisional Medical Officer, Indian Railway Health Services, Divisional Railway Hospital, Bhopal, India.
Ray Radha SargunamIndian Pharmacopeia Commission, Ministry of Health and Family Welfare, Ghaziabad, Uttar Pradesh, India.
Alagesan SrinivasanDepartment of Pharmaceutical Chemistry, College of Pharmacy, Madras Medical College, Chennai, India.
Eswaran ThangarajuT.S.M Jain College of Technology, Kallakurichi, Tamilnadu, India.
Tamilselvan ThangarajuSchool of Information Technology, SRM University, Sikkim, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionWithania somnifera (Ashwagandha) is a traditional herb that is currently commercially available for treating a variety of illnesses. By evaluating and verifying docking affinity scores, it is possible to explore the potential of the plant for treating leprosy and lepra-reaction as off-label use.

methodsThe sitoindosides were used as ligands along with thalidomide in docking against targets, such as M. leprae, TNF-Alpha, and Interleukin-6 in order to determine the potential for inhibitory concentration and docking affinity.

resultsAccording to the study, good binding energy values varied from -7 to -11 Kcal/mol. Sitoindoside IX had the highest binding affinity and important binding interactions, such as hydrogen bonding, when compared to Thalidomide and Sitoindoside X against all three receptors.

conclusionThe present study confirmed that the Sitoindoside IX and X are a better fit for treating patients with leprosy. These findings are highly intriguing and suggest that this herb should be investigated further to validate these findings in leprosy.

Indexed as

Leprostatic AgentsLeprosyMycobacterium lepraePlant ExtractsWithaniaHumansHydrogen BondingInterleukin-6Interleukin-6 InhibitorsLigandsMolecular Docking SimulationProtein BindingTumor Necrosis Factor-alphaAshwagandhaInterleukin-6Interleukin-6 InhibitorsLeprostatic AgentsLigandsPlant ExtractsTumor Necrosis Factor-alphaAshwagandhamolecular dockingmycobacterium lepraesitoindosidesthalidomide.Withania somnifera

Identifiers

PMID39757611

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.